GLAXO Q1 FY27 results at a glance
GLAXOSMITHKLINE PHARMA LT Q1 FY27 key results metrics| Quarter | Q1 FY27 |
|---|
| Quarter ended | 30 Jun 2026 |
|---|
| Revenue | ₹938 cr |
|---|
| Revenue YoY | +16.6% |
|---|
| Operating profit | ₹280 cr |
|---|
| Operating margin | 29.8% |
|---|
| Net profit | ₹237 cr |
|---|
| Net profit YoY | +15.7% |
|---|
| Net profit QoQ | -14.6% |
|---|
| Net margin | 25.3% |
|---|
| Basic EPS | ₹14.00 |
|---|
| TTM revenue | ₹3,780 cr |
|---|
| TTM net profit | ₹1,016 cr |
|---|
| TTM net margin | 26.9% |
|---|
GLAXO Q1 FY27 results: what the numbers say
GLAXOSMITHKLINE PHARMA LT (GLAXO) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹938 cr and a net profit of ₹237 cr, translating into earnings per share of ₹14.00.
Compared with the same quarter a year earlier, revenue grew by +16.6% and net profit grew by +15.7%. Profit trailing revenue growth suggests costs, interest or tax absorbed part of the topline gain.
Operating profit for the quarter stood at ₹280 cr, an operating margin of 29.8% versus 29.3% a year ago — a gain of 0.5 percentage points.
GLAXO quarter-wise results table
Net profit
₹237 cr
+15.7% YoY
Operating profit
₹280 cr
+18.7% YoY
GLAXOSMITHKLINE PHARMA LT (GLAXO) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q1 FY272026-06-30 | ₹938 cr | ₹280 cr | ₹237 cr | 29.8% | 25.3% | ₹14.00 | +15.7% | -14.6% |
| Q4 FY262026-03-31 | ₹995 cr | ₹338 cr | ₹278 cr | 33.9% | 27.9% | ₹16.40 | +5.7% | -6.0% |
| Q3 FY262025-12-31 | ₹1,041 cr | ₹351 cr | ₹296 cr | 33.7% | 28.4% | ₹17.45 | — | +44.2% |
| Q1 FY262025-06-30 | ₹805 cr | ₹236 cr | ₹205 cr | 29.3% | 25.5% | ₹12.10 | — | -22.0% |
| Q4 FY252025-03-31 | ₹974 cr | ₹318 cr | ₹263 cr | 32.7% | 27.0% | ₹15.52 | — | — |
| TTM (last 4 quarters) | ₹3,780 cr | ₹1,204 cr | ₹1,016 cr | 31.9% | 26.9% | ₹59.95 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
GLAXO quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
GLAXOSMITHKLINE PHARMA LT quarterly income statement| Particulars | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q1 FY262025-06-30 | Q4 FY252025-03-31 |
|---|
| Revenue / Sales | ₹938 cr | ₹995 cr | ₹1,041 cr | ₹805 cr | ₹974 cr |
|---|
| Total expenses | ₹659 cr | ₹658 cr | ₹690 cr | ₹569 cr | ₹656 cr |
|---|
| Gross profit | ₹611 cr | ₹651 cr | ₹677 cr | ₹517 cr | ₹622 cr |
|---|
| Operating profit (EBIT) | ₹280 cr | ₹338 cr | ₹351 cr | ₹236 cr | ₹318 cr |
|---|
| Operating margin | 29.8% | 33.9% | 33.7% | 29.3% | 32.7% |
|---|
| Interest cost | ₹0.97 cr | ₹0.61 cr | ₹1.19 cr | ₹0.42 cr | ₹0.58 cr |
|---|
| Profit before tax | ₹322 cr | ₹373 cr | ₹400 cr | ₹279 cr | ₹359 cr |
|---|
| Tax expense | ₹85.27 cr | ₹95.24 cr | ₹104 cr | ₹73.97 cr | ₹95.7 cr |
|---|
| Effective tax rate | 26.4% | 25.5% | 26.1% | 26.5% | 26.7% |
|---|
| Net profit (PAT) | ₹237 cr | ₹278 cr | ₹296 cr | ₹205 cr | ₹263 cr |
|---|
| Net profit margin | 25.3% | 27.9% | 28.4% | 25.5% | 27.0% |
|---|
| Basic EPS | ₹14.00 | ₹16.40 | ₹17.45 | ₹12.10 | ₹15.52 |
|---|
| Diluted EPS | ₹14.00 | ₹16.40 | ₹17.45 | ₹12.10 | ₹15.52 |
|---|
GLAXO results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q1 FY26 | Q4 FY25 |
|---|
| Revenue YoY | +16.6% | +2.1% | — | — | — |
|---|
| Revenue QoQ | -5.7% | -4.4% | +29.3% | -17.4% | — |
|---|
| Operating profit YoY | +18.7% | +6.1% | — | — | — |
|---|
| Operating profit QoQ | -17.2% | -3.8% | +48.9% | -26.0% | — |
|---|
| Net profit YoY | +15.7% | +5.7% | — | — | — |
|---|
| Net profit QoQ | -14.6% | -6.0% | +44.2% | -22.0% | — |
|---|
| EPS YoY | +15.7% | +5.7% | — | — | — |
|---|
| EPS QoQ | -14.6% | -6.0% | +44.2% | -22.0% | — |
|---|
GLAXO annual results history
Full-year performance for GLAXOSMITHKLINE PHARMA LT, useful for reading each quarter in context.
GLAXOSMITHKLINE PHARMA LT annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹3,808 cr | ₹3,726 cr | ₹3,442 cr | ₹3,226 cr |
|---|
| Total expenses | ₹2,560 cr | ₹2,612 cr | ₹2,603 cr | ₹2,478 cr |
|---|
| Gross profit | ₹2,386 cr | ₹2,253 cr | ₹2,022 cr | ₹1,868 cr |
|---|
| Operating profit (EBIT) | ₹1,248 cr | ₹1,114 cr | ₹838 cr | ₹748 cr |
|---|
| Operating margin | 32.8% | 29.9% | 24.4% | 23.2% |
|---|
| Interest cost | ₹2.73 cr | ₹1.31 cr | ₹1.8 cr | ₹1.81 cr |
|---|
| Profit before tax | ₹1,406 cr | ₹1,260 cr | ₹816 cr | ₹836 cr |
|---|
| Tax expense | ₹370 cr | ₹332 cr | ₹226 cr | ₹229 cr |
|---|
| Effective tax rate | 26.3% | 26.4% | 27.7% | 27.4% |
|---|
| Net profit (PAT) | ₹1,036 cr | ₹928 cr | ₹590 cr | ₹611 cr |
|---|
| Net profit margin | 27.2% | 24.9% | 17.1% | 18.9% |
|---|
| Basic EPS | ₹61.15 | ₹54.76 | ₹34.83 | ₹36.05 |
|---|
| Diluted EPS | ₹61.15 | ₹54.76 | ₹34.83 | ₹36.05 |
|---|
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹938 cr against ₹805 cr in Q1 FY26, and ₹995 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue declined -5.7%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹659 cr, or 70.2% of revenue, with operating profit grew +18.7% year on year.
Margins, tax and profitability
Net profit of ₹237 cr works out to a net margin of 25.3% compared with 25.5% in the year-ago quarter. Margin pressure of this kind usually reflects higher input costs, pricing competition, or a heavier interest and depreciation load.
Below the operating line, GLAXOSMITHKLINE PHARMA LT reported profit before tax of ₹322 cr, a tax charge of ₹85.27 cr (effective rate 26.4%), interest cost of ₹0.97 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹278 cr in Q4 FY26 to ₹237 cr in Q1 FY27, a change of -14.6%.
Trailing twelve months and annual context
Across the trailing four quarters GLAXOSMITHKLINE PHARMA LT has generated revenue of ₹3,780 cr and net profit of ₹1,016 cr, a trailing net margin of 26.9%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹3,808 cr with net profit of ₹1,036 cr and EPS of ₹61.15, versus the prior year where revenue grew +2.2% and profit grew +11.7%.
What to watch in the next GLAXO quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
GLAXOSMITHKLINE PHARMA LT has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
GLAXO results coverage
No results report published for GLAXO yet — our desk covers each quarter within minutes of the filing.
GLAXO quarterly results FAQs
What were GLAXOSMITHKLINE PHARMA LT (GLAXO) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), GLAXOSMITHKLINE PHARMA LT reported revenue of ₹938 cr and net profit of ₹237 cr, a change of +15.7% year on year on +16.6% revenue growth. EPS stood at ₹14.00.
What is GLAXO profit margin in Q1 FY27?
GLAXOSMITHKLINE PHARMA LT posted a net profit margin of 25.3% and an operating margin of 29.8% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹3,780 cr and net profit ₹1,016 cr.
Did GLAXO results beat the previous quarter?
GLAXOSMITHKLINE PHARMA LT net profit changed -14.6% quarter on quarter, from ₹278 cr in Q4 FY26 to ₹237 cr in Q1 FY27.
When are GLAXOSMITHKLINE PHARMA LT (GLAXO) quarterly results?
GLAXOSMITHKLINE PHARMA LT has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see GLAXO latest quarterly results?
Results coverage for GLAXO will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the GLAXO stock page.
What is GLAXOSMITHKLINE PHARMA LT annual revenue and profit?
For FY26, GLAXOSMITHKLINE PHARMA LT reported full-year revenue of ₹3,808 cr and net profit of ₹1,036 cr, with EPS of ₹61.15.
How many quarterly results has GLAXO declared recently?
Past results dates for GLAXO will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 12 Sept 2026. For information only, not investment advice.
